Human obesity trials were conducted, including a large programme that did not show a meaningful weight-loss benefit. That negative result is important evidence rather than a missing or inconclusive result.
Still uncertain: Meaningful weight-loss benefit, long-term safety, whether injectable use works, or a validated long-term treatment regimen.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
What does the evidence mean in simple terms? table
What is it?
Modified C-terminal hGH fragment peptide
Entity type
Peptide analogue / modified peptide
Research focus
Obesity/body-composition research
Human evidence
AOD-9604 underwent an oral obesity development programme. FDA's 2024 evidence review describes a 502-person randomized 24-week OPTIONS trial that found no statistically significant weight-loss difference versus placebo; an earlier 300-person dose-ranging study produced only small differences of unclear clinical importance.
Regulatory status
Not FDA-approved; FDA has raised compounding safety concerns.
Main limitations
Clinically meaningful weight-loss efficacy, long-term safety, injectable efficacy or a validated chronic-use regimen.
Safety
FDA cites limited safety information, potential immunogenicity/impurity issues and serious adverse events that may be associated, with causality unclear.
Evidence reviewed
2026-09-18
i
AOD-9604 underwent an oral obesity development programme. FDA's 2024 evidence review describes a 502-person randomized 24-week OPTIONS trial that found no statistically significant weight-loss difference versus placebo; an earlier 300-person dose-ranging study produced only small differences of unclear clinical import…
Outcome-level evidence
Evidence is not one score.
Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.
FDA cites limited safety information, potential immunogenicity/impurity issues and serious adverse events that may be associated, with causality unclear.
FDA cites limited safety information, potential immunogenicity/peptide-impurity concerns and serious adverse events reported in the programme with uncertain causality. Human non-oral route data are especially sparse.
Technical details
Mechanism / biologyC-terminal human growth-hormone fragment 177–191 with an added N-terminal tyrosine; developed to explore lipolytic effects without full GH activity.
Route / formulation boundaryResearch findings depend on verified AOD-9604 identity and route.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Study / label regimen evidenceHistorical human trial dosing verified. The Phase 2b OPTIONS programme studied oral 0.25 mg, 0.5 mg and 1 mg once daily for 24 weeks. The programme did not establish an approved therapeutic dose and should not be used to justify injectable marketplace protocols.
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
2structured study records
1outcome records
7linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
